Update on development of biosimilar versions of adalimumab with particular focus on excipients and injection site reactions

This updated document provides an overview of the five versions of adalimumab currently available in the UK, focusing on differences in excipients, in particular the evidence of the relationship between the presence of citrate and the incidence of injection site reactions.


Specialist Pharmacy Service